anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will employ an open-label, parallel-group design. Adult men and women who meet the inclusion/exclusion criteria and give written consent to participate will be assigned to one of the three groups according to their condition: Group A- normal volunteers; Group B- patients under dialysis; Group C- patients of cardiovascular high risk group. Each group will enroll 15 subjects. After two to four weeks run-in period, subjects will be given nattokinase orally for 8 weeks, and will be asked to stop taking nattokinase for 2 weeks to evaluate the effect of long-term intake and cease of intake of nattokinase.

Laboratory tests, including fibrinogen, T-PA, PAI-1, D-dimer, total cholesterol, LDL-C, HDL-C, and TG, vital signs and body weight will be evaluated at screening visit, 3 days, 1 week, 4 weeks, 8 weeks, and 10 weeks (2 weeks after cease of intake) visits. Patient self-evaluation of tolerance and physical improvement will be assessed by a Patient Questionnaire at 3-day, and 1-, 4-, 8-, and 10-week visits. Each patient will be carefully monitored for the development of any adverse events (AE).
FIELD: medicine. ^ SUBSTANCE: inventions relate to medicine, namely to cell transplantology, and deal with method and transplant for treatment of liver failure. For this purpose autologous progenitor cells of bone marrow are isolated and cultivated in vitro. Also realised is sampling of autologous liver cells. After that, immobilisation of autologous liver cells and progenitor cells of bone marrow on carrier - biodegradable biocompatible three-dimensional matrix is performed. After that, transplantation of carrier with cells is performed by its introduction into mesentery of small intestine. Transplant includes biodegradable biocompatible three-dimensional porous matrix with pore size 2-500 mcm and total porosity 50-97%, ensuring total concentration of liver cells and progenitor bone marrow cells 2ù106-15ù106 cells per 1 cm3 of matrix and ratio of progenitor bone marrow cells to liver cells from 1:1 to 1:4. Total volume of matrix constitutes not less than 0.05 cm3, its smallest linear size being not less than 0.2 mm. ^ EFFECT: inventions make it possible to improve results of liver failure treatment due to prolongation of terms of hepatocyte survival and activisation of their proliferation, creation of conditions for growing of vessels into creates carcass, diffusion of nutrients, oxygen and factors of tissue differentiation, make it possible to avoid application of immunosuppressive therapy. ^ 6 cl, 6 dwg
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that affects more than 7 million adults in the US. The prevalence of PAD increases with age and is estimated to be 15 20% among individuals 65 years of age and older. Patients with PAD have limited functional capacity; they walk more slowly and have less walking endurance than persons who do not have PAD, irrespective of whether they have classic symptoms of intermittent claudication or critical limb ischemia. This functional impairment adversely affects quality of life. Although flow limitation due to atherosclerotic stenosis is necessary for the development of symptoms in PAD, the lack of correlation between walking capacity and the degree of hemodynamic compromise raises the possibility that alternative mechanisms contribute to functional limitations in these patients. Putative mechanisms include inadequate skeletal muscle glucose uptake, altered skeletal muscle energetics, and impaired vasomotor tone and nutrient delivery mediated by endothelial dysfunction. Metformin, via AMPactivated protein kinase (AMPK)-dependent and independent mechanisms, can favorably affect skeletal muscle metabolic functions including glucose uptake, fatty acid oxidation, mitochondrial function, and consequently cellular energetics, and it also may have a direct salutary effect on vascular function via regulation of nitric oxide synthase. It is intriguing, therefore, to consider the possibility that metformin would improve skeletal muscle metabolic and vascular function in older patients with PAD and translate into functional benefits. Accordingly, the investigators seek to elucidate molecular mechanisms through which metformin affects skeletal muscle energetics and hypothesize that metformin will lead to advantageous metabolic, vascular, and physical functional changes in older patients with PAD.
PURPOSE:To obtain a whitening cosmetic containing a whey mineral consisting essentially of an unabsorbing fraction obtained by subjecting a whey to treatment with an ion exchange resin and/or its treated material, having excellent effect and free from trouble due to cosmetic and being safe. CONSTITUTION:Cheese whey and other whey are, as necessary after adjusting pH of the whey, treated with an ion exchange resin (especially preferably carboxymethylcellulose-based or sulfopropyl-cellulose-based ion exchange resin). An unabsorbing fraction obtained by this treatment is concentrated and cooled to crystallize lactose and the crystallized lactose is removed to afford whey mineral. Further, lactose in this whey mineral is partially removed from this whey mineral or a polymer material having >=100000 molecular weight is removed from this whey mineral to give a whey mineral treated material. At least one kind of mineral selected from a group of minerals obtained by this method is included to provide the objective whitening cosmetic. This cosmetic effectively utilizes a tyrosinase inhibitor contained in milk and a physiologically active substance contained in a polymer fraction.
The purpose of this study is to teach children with autism who do not produce sounds or words to vocalize sounds or words by using the stimulus-stimulus pairing (SSP) procedure. The investigators will use SSP, an intervention based in behavior analysis, to try to help the child vocalize sounds. A vocal recorder will also be sent home so that the caregiver can record the child's vocalization at home. The caregiver will then be asked to return this so that the investigators can listen to it. By doing this, the investigators hope to learn if the treatment helps increase the child's vocalizations at home. Some children in the study will receive treatment immediately. Some children may enroll in the study now but not receive intervention until a later date. All children in the study will receive treatment within one year of enrolling in the study.
BACKGROUND: Pulmonary hypertension (PH) can cause right ventricular (RV) failure and subsequent cardiohepatic syndrome referred to as congestive hepatopathy (CH). Passive blood stasis in the liver can affect inflammation, fibrosis, and ultimately cirrhosis. Cannabidiol (CBD) has many beneficial properties including anti-inflammatory and reduces RV systolic pressure and RV hypertrophy in monocrotaline (MCT)-induced PH in rats. Thus, it suggests that CBD may have the potential to limit CH development secondary to RV failure. The present study aimed to determine whether chronic administration of CBD can inhibit the CH secondary to RV hypertrophy associated with MCT-induced PH.
METHODS: The experiments involved rats with and without MCT-induced PH. CBD (10 mg/kg) or its vehicle was administered once daily for 3 weeks after MCT injection (60 mg/kg).
RESULTS: Monocrotaline administration increased the liver/body weight ratio. In histology examinations, we observed necrosis and vacuolar degeneration of hepatocytes as well as sinusoidal congestion. In biochemical studies, we observed increased levels of nuclear factor-κappa B (NF-κB), tumour necrosis factor-alpha (TNA-α), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6). CBD administration to PH rats reduced the liver/body weight ratio, improved the architecture of the liver, and inhibited the formation of necrosis. Cannabidiol also decreased the level of NF-κB, TNF-α, IL-1β and IL-6.
CONCLUSIONS: The studies show that CBD can protect the liver from CH probably through attenuating PH, protective effects on the RV, and possibly direct anti-inflammatory effects on liver tissue through regulation of the NF-κB pathway.
The MUC1 gene evolved in mammals for adaptation of barrier tissues in response to infections and damage. Paraspeckles are nuclear bodies formed on the NEAT1 lncRNA in response to loss of homeostasis. There is no known intersection of MUC1 with NEAT1 or paraspeckles. Here, we demonstrate that the MUC1-C subunit plays an essential role in regulating NEAT1 expression. MUC1-C activates the NEAT1 gene with induction of the NEAT1_1 and NEAT1_2 isoforms by NF-κB- and MYC-mediated mechanisms. MUC1-C/MYC signaling also induces expression of the SFPQ, NONO and FUS RNA binding proteins (RBPs) that associate with NEAT1_2 and are necessary for paraspeckle formation. MUC1-C integrates activation of NEAT1 and RBP-encoding genes by recruiting the PBAF chromatin remodeling complex and increasing chromatin accessibility of their respective regulatory regions. We further demonstrate that MUC1-C and NEAT1 form an auto-inductive pathway that drives common sets of genes conferring responses to inflammation and loss of homeostasis. Of functional significance, we find that the MUC1-C/NEAT1 pathway is of importance for the cancer stem cell (CSC) state and anti-cancer drug resistance. These findings identify a previously unrecognized role for MUC1-C in the regulation of NEAT1, RBPs, and paraspeckles that has been co-opted in promoting cancer progression.
Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
The invention discloses an amlodipine besylate membrane preparation comprising a strip-shaped membrane tape and an effective amount of loratadine loaded on the membrane tape. The strip-shaped membrane tape comprises an acidic strip-shaped membrane tape and an alkaline strip-shaped membrane tape which are connected and integrated. The acidic strip-shaped membrane tape and the alkaline strip-shaped membrane tape are spaced. According to the acidic strip-shaped membrane tape, a high-water-solubility high-molecular-weight film-forming material is adopted as a main body; calculated according to the weight of the acidic membrane tape, the tape comprises 1-20% of an acidic agent. According to the alkaline strip-shaped membrane tape, a high-water-solubility high-molecular-weight film-forming material is adopted as a main body; calculated according to the weight of the alkaline membrane tape, the tape comprises 1-20% of an alkaline agent. When the preparation contacts water, the membrane forms an effervescent, and a large amount of air bubbles are formed. Olfactory is paralyzed, such that an odor covering effect is achieved. Also, dissolution can be accelerated.
Laryngeal schwannomas are rare benign neurogenic tumors of the larynx. They cannot be detected in the early stages because disease onset is asymptomatic. This case of laryngeal schwannoma provided a reference for clinical diagnosis and treatment strategy. A 24-year-old man presented with a 3-year history of hoarseness and sore throat for 6 months. Laryngoscopy and computed tomography showed submucosal bulging of the right ventricular fold in the right paraglottic space. The patient underwent tracheotomy first, followed by laryngotomy. The edema of the laryngeal mucosa was significantly alleviated, with normal movement of the bilateral vocal cords on the 10th day after surgery. The tracheal tube was removed at the time of discharge. The hoarseness had disappeared at the end of the first month after surgery. The effective treatment of laryngeal schwannoma involves complete resection with surgery while protecting the integrity of the larynx and restoring laryngeal function. The indication for surgery should be strictly controlled to avoid damage to the mucosa and structures of the larynx.
The zinc finger protein CTCF is ubiquitously expressed and is integral to the regulation of chromatin architecture through its interaction with cohesin. Conversely, CTCFL expression is predominantly restricted to the adult male testis but is aberrantly expressed in certain cancers. Despite their distinct expression patterns, the cooperative and competitive mechanisms by which CTCF and CTCFL regulate target gene expression in spermatocytes and cancer cells remain inadequately understood. In this review, we comprehensively examine the literature on the divergent amino acid sequences, target sites, expression profiles and functions of CTCF and CTCFL in normal tissues and cancers. We further elucidate the mechanisms by which CTCFL competitively or cooperatively binds to CTCF target sites during spermatogenesis and carcinogenesis to modulate chromatin architecture. We mainly focus on the role of CTCFL in testicular and cancer development, highlighting its interaction with CTCF at CTCF binding sites to regulate target genes. In the testis, CTCF and CTCFL cooperate to regulate the expression of testis-specific genes, essential for proper germ cell progression. In cancers, CTCFL overexpression competes with CTCF for DNA binding, leading to aberrant gene expression, a more relaxed chromatin state, and altered chromatin loops. By uncovering the roles of CTCF and CTCFL in spermatogenesis and carcinogenesis, we can better understand the implications of aberrant CTCFL expression in altering chromatin loops and its contribution to disease pathogenesis.
PURPOSE: To form a stable complex compound and retain its color hue stably for a long time and to improve diagnosis accuracy by adding a predetermined amount of nickel to a reagent and preparing it. CONSTITUTION: The reagent consists of mercury for generating complex compounds, nickel for crosslinking and stabilizing the complex compounds, nitric acid for converting tyrosine into nitroso, and distilled water as a dispersing material. By setting the amount of added nickel to mercury 1 to 0.05 pts.wt. or less in the blend ratio of mercury and nickel, a produced deposit becomes unstable. On the other hand, by setting it to 0.5 pts.wt. or more, the amount of produced deposit decreases, thus making difficult an highly accurate diagnosis. Therefore, with the blend ratio, the amount of added nickel to the mercury 1 pts.wt. is set to a range of 0.05-0.5 pts.wt.
PURPOSE:To obtain the titled ester stable to the first fluid according to the Pharmacopoeia of Japan, by reacting a specified hydroxypropoxyl group- containing cellulose ether with a dicarboxylic acid anhydride in the presence of an alkali metal acetate and acetic acid. CONSTITUTION:A viscous liquid is obtained by reacting a hydroxyl group- containing cellulose ether (A) having a viscosity of its 2% aqueous solution of 50-70cP with a dicarboxylic acid anhydride (e.g., phthalic anhydride) or a mixture (B) thereof with an aliphatic monocarboxylic acid anhydride (e.g., acetic anhydride) at 60-90 deg.C for 2-8hr in the presence of 50-150pts.wt. alkali metal acetate (e.g., sodium acetate) and 200-700pts.wt. acetic acid per 100pts.wt. component A. The obtained liquid is mixed with a large amount of water and the precipitate is filtered, washed with water to remove impurities and dried to obtain a powdered acidic dicarboxylic acid ester of cellulose ether.
The Glaspey Dynamic Assessment of Phonology (GDAP) (Glaspey, 2006; Glaspey \& Stoel-Gammon, 2007) was initially developed because children with speech-sound delays make very slow progress in speech therapy and it is difficult to document change in short periods of time using traditional methods of assessment. The traditional methods rely on picture-naming tasks and the child is not given any assistance in speech productions. The lack of assistance often results in a floor effect in the documentation of change and progress. Without good documentation of change, speech-language pathologists are left uncertain about the efficacy of the treatment that they are administering. The GDAP is unique because it assesses change based on dynamic assessment; children are systematically given assistance in the production of speech sounds. When administering the GDAP, clinicians rate each sound on a 15-point ordinal scale that represents the number of cues and assistance that could be used to assist the child in sound production. Progress is documented as children need less support over time and their scores decrease. This study compares the GDAP with a traditional single-word measure. This study also has an extension to use the GDAP to select easier or harder targets during treatment, and monitor children's progress across measures over 8 weeks of modified cycles treatment. The treatment will include 16 sessions of therapy with two 50-minute sessions per week. The treatment approach that will be used is called "Cycles" and involves practicing a different speech sound each week (Rudolf \& Wendt, 2014). The sounds that are practiced will be individualized to each child's needs, with harder sounds taught during four of the weeks and easier sounds taught during four of the weeks. The order will be counter-balanced across participants.
In patients with definite or suspected acute myocardial infarction, treatment with TENORMIN I.V. Injection should be initiated as soon as possible after the patient's arrival in the hospital and after eligibility is established. Such treatment should be initiated in a coronary care or similar unit immediately after the patient's hemodynamic condition has stabilized. Treatment should begin with the intravenous administration of 5 mg TENORMIN over 5 minutes followed by another 5 mg intravenous injection 10 minutes later. TENORMIN I.V. Injection should be administered under carefully controlled conditions including monitoring of blood pressure, heart rate, and electrocardiogram. Dilutions of TENORMIN I.V. Injection in Dextrose Injection USP, Sodium Chloride Injection USP, or Sodium Chloride and Dextrose Injection may be used. These admixtures are stable for 48 hours if they are not used immediately.

In patients who tolerate the full intravenous dose (10 mg), TENORMIN Tablets 50 mg should be initiated 10 minutes after the last intravenous dose followed by another 50 mg oral dose 12 hours later. Thereafter, TENORMIN can be given orally either 100 mg once daily or 50 mg twice a day for a further 6 to 9 days or until discharge from the hospital. If bradycardia or hypotension requiring treatment or any other untoward effects occur, TENORMIN should be discontinued. (See full prescribing information prior to initiating therapy with TENORMIN Tablets.)

Data from other beta-blocker trials suggest that if there is any question concerning the use of I.V. beta-blocker or clinical estimate that there is a contraindication, the I.V. beta-blocker may be eliminated and patients fulfilling the safety criteria may be given TENORMIN Tablets 50 mg twice daily or 100 mg once a day for at least seven days (if the I.V. dosing is excluded). 

Although the demonstration of efficacy of TENORMIN is based entirely on data from the first seven postinfarction days, data from other beta-blocker trials suggest that treatment with beta-blockers that are effective in the postinfarction setting may be continued for one to three years if there are no contraindications.

TENORMIN is an additional treatment to standard coronary care unit therapy.
Carbohydrate antigens are a common feature of cancer cells and pathogens, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV).  Carbohydrates cannot activate helper T-cells and have poor immunogenicity. This invention provides a novel glycolipopeptide to generate antibodies to carbohydrate antigens. The glycolipopetide includes at least one B-epitope, at least one T-epitope, and a lipid component. The invention also includes a method for making the glycolipopeptide of the invention. The invention also provides a polyclonal or monoclonal antibody against the glyeolipopetitde of the invention.  The invention also includes a pharmaceutical composition including the glycolipopeptide.
Provided is an earthworm protein peptide for preparing a medicine for treating a thrombotic disease. The earthworm protein peptide is any one selected from a group consisting of Leu-Val-Thr-Leu-Gly-Asn-Glu (SEQ ID NO.: 1), Leu-Leu-Ala-Pro-Pro (SEQ ID NO: 2), Leu-Leu-Pro-Ala-Pro (SEQ ID NO: 3) and Thr-Val-Ala-Pro-Phe (SEQ ID NO: 4). The earthworm protein peptide can significantly inhibit the thrombin activity, thus achieving the anticoagulant effect. In vivo, the earthworm protein peptide has a significant inhibitory effect on carrageenan-induced rat tail thrombosis; and in vitro and in vivo studies of rats with thrombus, the earthworm protein peptide provided by the present invention shows good anticoagulant effects. The earthworm protein peptide has effects of thrombosis inhibition, thrombolysis, anticoagulation and fibrinolysis promotion, and can effectively prevent and treat thrombotic disease.
Taxanes are a class of chemotherapy agents that promote the polymerization of tubulin into highly stable, intracellular microtubules. These microtubules cause cell death by interfering with normal cell division. (1,2) The first taxane developed and tested in the field of oncology was paclitaxel.(3,4 )The introduction of paclitaxel to the armamentarium of oncologic therapy in the early 1990s had a great impact on the standard of care in lung carcinoma, breast carcinoma, ovarian carcinoma, and other solid tumors. Subsequent to this development, another taxane, docetaxel was introduced. (5,6) Unfortunately, taxane therapy is associated with side effects such as peripheral neuropathy, myelosuppression, arthralgias, myalgias, and skin reactions that may adversely affect patient-reported quality of life (QOL). Peripheral neuropathy in particular can be severe. This toxicity is cumulative across the course of therapy, can be a dose-limiting toxicity, and may lead to dose reduction or cessation of therapy. (7) Peripheral neuropathies encompass disorders of peripheral nerve cells and fibers which manifest secondary to a wide range of pathologies. These nerves include cranial nerves, spinal nerve roots \& ganglia, nerve trunks \& division, along with nerves of the autonomic nervous system. The most frequently encountered symptoms of peripheral neuropathy include numbness and paresthesias , pain, weakness, and loss of deep tendon reflexes may accompany these symptoms. (8) Vitamin D is a fat-soluble vitamin that plays an important role in calcium homeostasis and bone metabolism, vitamin-D deficiency is associated with osteoporosis, increased risk of falls and fragility fractures. Many conflicting recent studies are now showing an association between vitamin D deficiency and cancer, cardiovascular disease, diabetes, autoimmune diseases, and depression. (9) Initial supplementation for 8 weeks with Vitamin D3 either 6,000 IU daily or 50,000 IU weekly can be considered. Once the serum 25-hydroxyvitamin D level exceeds 30 ng/mL, a daily maintenance dose of 1,000 to 2,000 IU is recommended. A higher-dose initial supplementation with vitamin D3 at 10,000 IU daily may be needed in high-risk adults who are vitamin D deficient (African Americans, Hispanics, obese, taking certain medications, malabsorption syndrome). Once serum 25-hydroxyvitamin D level exceeds 30ng/mL, 3000 to 6000 IU/day maintenance dose is recommended.(10) A 2022 ASCO meeting abstract by Chen et al reported that patients with vitamin D deficiency had more paclitaxel-induced neuropathy than those with normal vitamin D blood concentrations. (11)
The participants will start with passive mobilization right after surgery for 4 weeks. Intervention in hydrotherapy will follow after that.